Hims & Hers Stock Surges as Telehealth Platform Adds Eli Lilly Weight-Loss Drugs [Yahoo! Finance]
Hims & Hers Health, Inc. Class A (HIMS)
Company Research
Source: Yahoo! Finance
The treatments will each cost $1,899 per month, according to the company's website. Hims shares have more than doubled in value over the past 12 months. Hims & Hers Health ( HIMS ) shares jumped Tuesday as the company added Eli Lilly's ( LLY ) weight-loss drug Zepbound and diabetes drug Mounjaro to its roster of telehealth treatments. The company said it will now offer branded tirzepatide, the active ingredient in both Eli Lilly drugs. It also added a generic version of Novo Nordisk's ( NVO ) liraglutide, which is used to treat Type 2 diabetes. Zepbound and Mounjaro will cost $1,899 per month through Hims, while liraglutide will cost $299, according to the company's website. Shares of Hims rose 5% Tuesday. They've more than doubled in value over the past 12 months, despite taking a hit in recent weeks after the Food and Drug Administration said in February that a shortage of the active ingredient in Novo Nordisk's Wegovy and Ozempic was resolved. Hims has manufactured copyc
Show less
Read more
Impact Snapshot
Event Time:
HIMS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HIMS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HIMS alerts
High impacting Hims & Hers Health, Inc. Class A news events
Weekly update
A roundup of the hottest topics
HIMS
News
- Hims stock falls after lawmakers propose GLP-1 compounding restrictions [Yahoo! Finance]Yahoo! Finance
- Hims & Hers Health (NYSE:HIMS) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.MarketBeat
- Hims & Hers Brings Comprehensive Weight Loss Programme to the UKBusiness Wire
- What Analysts Think Is Changing the Hims and Hers Story for Long Term Investors [Yahoo! Finance]Yahoo! Finance
- Hims & Hers Health (NYSE:HIMS) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.MarketBeat
HIMS
Earnings
- 11/3/25 - Miss
HIMS
Sec Filings
- 12/18/25 - Form 4
- 12/18/25 - Form 4
- 12/18/25 - Form 4
- HIMS's page on the SEC website